Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash, securing a clinical-stage JAK2 inhibitor for myeloproliferative neoplasms. Ajax’s lead asset, AJ1-11095, is a Type II JAK2 inhibitor being studied in Phase 1 for myelofibrosis. The deal further reinforces Lilly’s strategy of using acquisitions to widen its hematology pipeline, including a continued emphasis on next-generation mechanisms designed to improve durability versus existing JAK inhibitor regimens. For Ajx, Lilly’s resources may accelerate clinical proof-of-concept and registrational planning. While Lilly highlighted AJ1-11095’s potential for deeper and more durable disease control, the market will likely focus on interim clinical endpoints and safety/tolerability as Phase 1 progresses. The structure also leaves room for milestone-driven valuation tied to future development and regulatory outcomes. Overall, the transaction adds another major contender to the competitive landscape of therapies aimed at sustained responses in myelofibrosis and related disorders.